Cookie Control

This site uses cookies to store information on your computer.

Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.

We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.

By using our site you accept the terms of our Privacy Policy.

(One cookie will be set to store your preference)
(Ticking this sets a cookie to hide this popup if you then hit close. This will not store any personal information)

"Drugs Standards Group Nixes Plan To Kick Pharma's Crab Blood Habit"

"ZURICH - Horseshoe crabs’ icy-blue blood will remain the drug industry’s standard for safety tests after a powerful U.S. group ditched a plan to give equal status to a synthetic substitute pushed by Swiss biotech Lonza and animal welfare groups.

The crabs’ copper-rich blood clots in the presence of bacterial endotoxins and has long been used in tests to detect contamination in shots and infusions.

More recently, man-made versions called recombinant Factor C (rFC) from Basel-based Lonza and others have emerged.

An industry battle has been brewing, as another testing giant, Lonza’s U.S.-based rival Charles River Laboratories, has criticized the synthetic option on safety grounds."

John Miller reports for Reuters May 30, 2020.

Source: Reuters, 06/01/2020